Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|June 1, 2016
Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different PopulationsPhilip J Bergin, Robert Langat, Gloria Omosa-Manyonyi, et al.
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 30, 2013
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1Nicola Borthwick, Tina Ahmed, Beatrice Ondondo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2021
A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral SyndromeAmin S Hassan, Jonathan Hare, Kamini Gounder, et al.
Plos Pathogens|August 27, 2019
Protective HLA alleles are associated with reduced LPS levels in acute HIV infection with implications for immune activation and pathogenesisDaniel T Claiborne, Eileen P Scully, Christine D Palmer, et al.
AIDS Research and Human Retroviruses|June 12, 2008
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccineSanjay Mehendale, Jan van Lunzen, Nathan Clumeck, et al.
Nature Communications|December 5, 2024
Dynamics of the blood plasma proteome during hyperacute HIV-1 infectionJamirah Nazziwa, Eva Freyhult, Mun-Gwan Hong, et al.
Plos One|May 1, 2008
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trialsWendy Stevens, Anatoli Kamali, Etienne Karita, et al.
Plos Pathogens|December 5, 2012
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesisJessica L Prince, Daniel T Claiborne, Jonathan M Carlson, et al.
Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.
Pageof 12